CYP2D6-Guided Opioid Therapy for Chronic Pain: A Multi-Center Pragmatic Randomized Controlled Trial.

CYP2D6

CYP2D6-mediated metabolism of tramadol, hydrocodone and codeine into more active opioid receptor agonists

This pragmatic multi-center randomized controlled trial tested whether CYP2D6-guided opioid prescribing improves chronic pain. Adults with at least 3 months of chronic pain treated or considered for tramadol, hydrocodone or codeine were randomized to usual care or to a CYP2D6-guided arm, where prescribers were advised to avoid these three opioids in intermediate, poor or ultra-rapid (for safety) metabolizers, based on genotype or drug interactions. Of 1,048 enrolled participants, 282 had an actionable CYP2D6 phenotype. In this group, the primary outcome — change in composite pain intensity score from baseline to 3 months — was not improved by guided recommendations (mean [SD] -0.8 [2.4] vs. -0.7 [2.3]), nor was drug-gene concordance (26.8% vs. 27.1%). In an exploratory analysis, participants whose therapy was actually changed to align with their CYP2D6 phenotype had significantly improved pain scores.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

A negative trial on its primary outcome, and the authors read it accordingly: the EHR-integrated CYP2D6 alert did not change prescribing, with drug-gene concordance identical in both arms. This is an implementation failure rather than a refutation of tramadol and codeine pharmacogenetics, as the exploratory signal in patients whose therapy actually changed suggests — but that subgroup is self-selected and proves nothing. The practical lesson is that making a genotype available is not the same as changing practice: without prescriber support, the information goes unused.

Analysis by Dr Thibaut Benquey